ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.Journal for immunotherapy of cancer · 2021Pooled it
- Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.Hepatology (Baltimore, Md.) · 2019Trial
- MYCN-driven metabolic remodelling of the tumour microenvironment in neuroblastoma: implications for stromal biology and CAF heterogeneity.Cancer metastasis reviews · 2026Review
- Bridging cancer cell-intrinsic driver genes and -extrinsic cell-cell communication with Driver2Comm.PLoS computational biology · 2026Article
- Longitudinal single-cell analysis identifies a chemotherapy-suppressed proliferative program associated with adverse prognosis in neuroblastoma.Frontiers in genetics · 2026Article
- Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma.Cell reports. Medicine · 2025Article
- Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma.The Journal of experimental medicine · 2025Article
- Prediction of neuroblastoma prognosis with a novel T-cell exhaustion-related gene signature.Scientific reports · 2025Article
- Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical Outcomes.International journal of molecular sciences · 2025Review
- Loss of ARID1A leads to a cold tumor phenotype via suppression of IFNγ signaling.Scientific reports · 2025Article
- EDF1 accelerates ganglioside GD3 accumulation to boost CD52-mediated CD8Journal of experimental & clinical cancer research : CR · 2025Article
- T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma.Frontiers in immunology · 2025Review
- Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors.Cytotherapy · 2025Article
- Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives.Cancer metastasis reviews · 2024Review
- Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma.Discover oncology · 2024Article
- Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.Journal for immunotherapy of cancer · 2024Article
- Review
- Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures.Cancer research communications · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Jun S Wei *Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Igor B Kuznetsov *Cancer Research Center and Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Rensselaer, New York.
Shile Zhang *Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Young K SongOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Shahab AsgharzadehDivision of Hematology/Oncology, the Children's Hospital Los Angeles, Los Angeles, California.
Sivasish SindiriOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Xinyu WenOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Rajesh PatidarOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Sushma NajarajOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ashley WaltonOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Jaime M Guidry AuvilOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland.
Daniela S GerhardOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland.
Aysen YukselThe Tumour Bank, Children's Cancer Research Unit, Kids Research Institute, the Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Daniel CatchpooleThe Tumour Bank, Children's Cancer Research Unit, Kids Research Institute, the Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Stephen M HewittExperimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Paul M SondelDepartments of Pediatrics, Human Oncology and Genetics, the University of Wisconsin, Madison, Wisconsin.
Robert SeegerDivision of Hematology/Oncology, the Children's Hospital Los Angeles, Los Angeles, California.
John M MarisDepartment of Pediatrics, University of Pennsylvania and Center for Childhood Cancer Research, the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Javed KhanOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. khanjav@mail.nih.gov.
National Cancer Institute · USChildren's Hospital at Westmead · AUChildren's Hospital of Los Angeles · USChildren's Hospital of Philadelphia · USUniversity at Albany, State University of New York · USUniversity of Wisconsin–Madison · US
Funding
BIOINFORMATICS: SYSTEMS BIOLOGY OF PEDIATRIC CANCERSZIABC011002 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$9.3MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MIdentifying Strategies to Increase Engagement in Clinical Trials in Pediatric SCDRC1MD004418 · NIMHD · CHILDREN'S HOSP OF PHILADELPHIA · PI BARAKAT, LAMIA P · 2009 to 2010
$813kIntramural NIH HHS Z99 CA999999NCI NIH HHS R35 CA197078NIMHD NIH HHS RC1 MD004418
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell Line, TumorChild, PreschoolComputational BiologyCytotoxicity, ImmunologicGene AmplificationGene Expression Regulation, NeoplasticHumansInfantInfant, NewbornNeoplasm StagingNeuroblastomaN-Myc Proto-Oncogene ProteinReceptors, Antigen, T-CellT-LymphocytesTranscriptomeN-Myc Proto-Oncogene ProteinReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.